Business Context and Reporting Period
This Form 6-K filing by Cellyan Biotechnology Co., Ltd. covers the month of July 2026, with the report dated July 16, 2026. The filing addresses the Company's compliance status with Nasdaq Stock Market listing requirements regarding its common stock bid price.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance matters rather than financial performance.
Material Changes
The primary material event is the extension of the grace period to regain compliance with the Nasdaq Minimum Bid Price Requirement ($1.00 per share). Previously notified of non-compliance on January 12, 2026, the Company received a notice on July 14, 2026, granting an additional 180 days to meet the requirement.
Outlook, Risks, and Management Commentary
- Compliance Deadline: The new deadline to regain compliance with the Minimum Bid Price Requirement is January 11, 2027.
- Risk of Delisting: Failure to maintain the minimum bid price by the new deadline may result in delisting from the Nasdaq Stock Market.
- Management Action: The Company has incorporated this report by reference into its Form F-3 registration statement.
Investor Verification Checklist
- Verify the current closing bid price of Cellyan Biotechnology Co., Ltd. common stock to assess progress toward the $1.00 threshold.
- Review the press release (Exhibit 99.1) for specific details on the Company's plan to regain compliance.
- Monitor future filings for any further notices from the Nasdaq Listing Qualifications Staff regarding compliance status.